Cherofsky Keriann sold $137K of IQV

Cherofsky Keriann (See Remarks) sold 558 shares of IQVIA HOLDINGS INC. (IQV) at $245.21 ($0.14M total) on 2026-07-29.

Original reporting
SEC EDGAR · Cherofsky Keriann
Published Jul 31, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

Insider open-market sales can be interpreted as sentiment signals, but without additional company-specific information, the trading impact is typically limited.

02

Market read

A modest insider sale was disclosed via Form 4, offering limited incremental information for trading decisions.

03

What to watch

The article does not state whether the insider’s remaining holdings are part of a broader pattern, nor does it provide context on compensation, vesting, or prior sales frequency.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31, sale dated 2026-07-29

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer Cherofsky Keriann sold 558 shares at $245.21 on 2026-07-29 for about $136.8K, after which she held 2,989 shares.

Expected impact

Likely negligible near-term price impact; any effect would be limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value (~$137K) is modest relative to IQVIA’s market scale, and the article provides no accompanying corporate event, guidance, or legal/regulatory development.

Market effects

No sector read-through is provided beyond a single insider sale at a large healthcare/clinical research services company.

None indicated.

None indicated.

Counterpoint

The sale could be driven by personal liquidity needs or tax planning rather than a bearish view, especially since the filing does not include any negative company-specific catalyst.

Key entities

  • IQVIA Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Cherofsky Keriann

    Officer who sold 558 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.